Rep.-elect Adelita Grijalva is expected to be sworn in when the House returns to vote on a possible end to the government ...

Phase 2a data support oral C5aR inhibitor INF904 as a potentially transformational and best-in-class immunomodulatory agent, indicating strong potential for efficacy and no safety signals of concernIn ...

Resolution Therapeutics announces new data showcasing the potential of Regenerative Macrophage Therapy in treating cirrhosis at AASLD 2025 New clinical data from the MATCH Phase II study shows early ...

Good afternoon and happy Monday, readers! We are getting closer to the end of the longest government shutdown. All eyes are ...

Adjusted basic and diluted net income per ADS attributable to KE Holdings Inc.’s ordinary shareholders 11 were RMB1.17 (US$0.16) and RMB1.12 (US$0.16) in the third quarter of 2025, respectively, ...

Damora Therapeutics, the sixth company launched based on assets developed by Paragon Therapeutics, is advancing a portfolio of anti-mutant calreticulin (mutCALR) targeted therapies, led by DMR-001, a ...